Partners Wealth Management LLC Invests $206,000 in Pfizer Inc. (NYSE:PFE)

Partners Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, Holdings Channel.com reports. The firm bought 7,760 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. South Dakota Investment Council increased its stake in shares of Pfizer by 0.7% during the 4th quarter. South Dakota Investment Council now owns 1,348,986 shares of the biopharmaceutical company’s stock valued at $35,789,000 after acquiring an additional 9,000 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Pfizer in the fourth quarter valued at approximately $4,322,000. World Equity Group Inc. increased its position in Pfizer by 36.0% during the fourth quarter. World Equity Group Inc. now owns 89,682 shares of the biopharmaceutical company’s stock worth $2,372,000 after purchasing an additional 23,729 shares during the last quarter. Delta Financial Group Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $2,564,000. Finally, Ascent Wealth Partners LLC raised its stake in Pfizer by 1.0% during the fourth quarter. Ascent Wealth Partners LLC now owns 75,588 shares of the biopharmaceutical company’s stock worth $2,005,000 after purchasing an additional 734 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Trading Up 1.6 %

NYSE PFE opened at $26.32 on Monday. The stock has a market cap of $149.14 billion, a P/E ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. The company’s fifty day simple moving average is $26.30 and its 200-day simple moving average is $27.40. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Analyst Ratings Changes

A number of analysts have recently commented on PFE shares. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.